Expert Consensus on Characteristics, Etiology, and Management of Chorioretinal Atrophy in Patients Treated with Voretigene Neparvovec
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Andreas Clemens (ORCID: https://orcid.org/0000-0001-6192-1557)
- Line Kessel (ORCID: https://orcid.org/0000-0002-9375-1510)
- Štingl Katarina
- M.Dominik Fischer
- David L. Rousso
- Isabelle Audo
- Stephen Russell
- Bart P. Leroy
- Rainer Maier
- Frank G. Holz
- David Gaucher
- Aaron Nagiel
Institutions
- University of Southern California (US)
- University of Copenhagen (DK)
- University of Iowa (US)
- Novartis (Switzerland) (CH)
- Centre National de la Recherche Scientifique (FR)
- Children's Hospital of Los Angeles (US)
- Institut de la Vision (FR)
- University of Bonn (DE)
- Inserm (FR)
- Centre hospitalier national d'ophtalmologie des Quinze-Vingts (FR)
- Ghent University Hospital (BE)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Ghent University (BE)
- Sorbonne Université (FR)
- University of Oxford (GB)
- Southern California Eye Institute (US)
- Spark Therapeutics (United States) (US)
- Kaiser Permanente South San Francisco Medical Center (US)
- STZ eyetrial (DE)
- Oxford BioMedica (United Kingdom) (GB)
- Hôpital Civil, Strasbourg (FR)
- Université de Strasbourg (FR)
- University of Tübingen (DE)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1016/j.xops.2026.101090
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00